Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Everest Medicines Reports In-licensed Candidate Effective for Rare Kidney Disease

publication date: Jun 22, 2023

Shanghai Everest Medicines reported that a partnered rare disease drug, a treatment for the kidney disease,  IgA nephropathy (IgAN), was effective in a Phase III trial conducted by Sweden’s Calliditas Therapeutics. In 2019, Everest entered a $121 million deal for China rights to Nefecon from Calliditas. Nefecon is an oral delayed release formulation of budesonide, a corticosteroid with potent glucocorticoid activity. The results of the Phase III trial showed a statistically significant improvement compared to placebo. Everest said it expects to release data from a cohort of China patients in Q3 of 2023. More details....

Stock Symbols: (HK: 1952) (NSDQ: CALT)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here